TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03573531

Intervention type: OTHER
Intervention: Laboratory analysis
Description: Analysis of lipid peroxidation markers (malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-PGF2α) Analysis of fatty acid content Analysis of total antioxidant capacity

Intervention type: OTHER
Intervention: Laboratory analysis
Description: Analysis of lipid peroxidation markers (malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-PGF2α) Analysis of fatty acid content Analysis of total antioxidant capacity

Intervention type: OTHER
Intervention: Laboratory analysis
Description: Analysis of lipid peroxidation markers (malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-PGF2α) Analysis of fatty acid content Analysis of total antioxidant capacity
Study: NCT05011786

Intervention type: PROCEDURE
Intervention: hernia repair/ligation of the hernial sac
Description: the inguinal hernia sac is ligated using sutures at the level of internal ring throught an inguinal incision in the open group and using laparoscopic instruments in the laparoscopic group

Intervention type: PROCEDURE
Intervention: hernia repair/ligation of the hernial sac
Description: the inguinal hernia sac is ligated using sutures at the level of internal ring throught an inguinal incision in the open group and using laparoscopic instruments in the laparoscopic group
Study: NCT01960452

Intervention type: BEHAVIORAL
Intervention: Serial awakenings
Description: The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.

Intervention type: BEHAVIORAL
Intervention: Serial awakenings
Description: The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.
Study: NCT00396097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
Study: NCT04021537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive nerve stimulation
Description: Electrical stimulation will be provided via a TENS unit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive nerve stimulation
Description: Electrical stimulation will be provided via a TENS unit.
Study: NCT00658138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M ESPE Adper Scotchbond SE
Description: To be used per manufacturer's instructions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M ESPE Adper Scotchbond 1XT
Description: To be used per manufacturer's instructions.
Study: NCT03319082

Intervention type: COMBINATION_PRODUCT
Intervention: Corneal Collagen Cross-linking
Description: Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
Study: NCT04131595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-WEV Dose 1
Description: 1 x 10\^7 Inf.U MVA-BN-WEV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-WEV Dose 2
Description: 1 x 10\^8 Inf.U MVA-BN-WEV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-WEV Dose 3
Description: 2 x 10\^8 Inf.U MVA-BN-WEV vaccine.
Study: NCT04013412

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-Calorie Restriction
Description: Four day dietary intervention immediately before surgery of ScandiShake \[any of 4 flavors\] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
Study: NCT03052114

Intervention type: DEVICE
Intervention: Electrical Impedance Tomography
Description: EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt.

Intervention type: DEVICE
Intervention: Electrical Impedance Tomography
Description: EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt.
Study: NCT01913106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSV-tk +Valacyclovir in Combination with Brachytherapy
Description: The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or vehicle to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein.
Study: NCT04609826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-74856665
Description: JNJ-74856665 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-74856665
Description: JNJ-74856665 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-74856665
Description: JNJ-74856665 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-74856665
Description: JNJ-74856665 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZA
Description: AZA will be administered IV infusion or SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN
Description: VEN tablet will be administered orally.
Study: NCT04153149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vutrisiran
Description: Vutrisiran will be administered by SC injection.
Study: NCT04153149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vutrisiran
Description: Vutrisiran will be administered by SC injection.
Study: NCT01739218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at a dose calculated according to the Calvert formula (\[participant's glomerular filtration rate + 25\] multiplied by the target area under the concentration-time curve \[AUC\] of 5 milligrams per milliliter per minute \[mg/mL/min\]), as intravenous \[IV\] infusion over 30-60 minutes \[min\] every 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at a dose calculated according to the Calvert formula (\[participant's glomerular filtration rate + 25\] multiplied by the target area under the concentration-time curve \[AUC\] of 5 milligrams per milliliter per minute \[mg/mL/min\]), as intravenous \[IV\] infusion over 30-60 minutes \[min\] every 3 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 milligrams per meter-squared \[mg/m\^2\] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m\^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 milligrams per meter-squared \[mg/m\^2\] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m\^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
Study: NCT04153149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Sterile normal saline (0.9% NaCl) will be administered by SC injection.
Study: NCT03794375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed.
Study: NCT01739218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 milligrams per kilogram \[mg/kg\] as IV infusion over 30-90 min every 3 weeks.
Study: NCT03794375

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
Study: NCT04312672

Intervention type: BIOLOGICAL
Intervention: AAV5-hRKp.RPGR
Description: Participants will not receive any intervention in this study. Participants from the retrospective (MGT009-NCT03252847) study will be follow-up.
Study: NCT01853631

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells
Description: Three dose levels will be evaluated.~Group 1: CD19.CAR/28137ζ at 1×10\^6 cells/m\^2 and CD19.CAR/28ζ at 1×10\^6 cells/m\^2~Group 2: CD19.CAR/28137ζ at 5×10\^6 cells/m\^2 and CD19.CAR/28ζ at 5×10\^6 cells/m\^2~Group 3: CD19.CAR/28137ζ at 2×10\^7 cells/m\^2 and CD19.CAR/28ζ at 2×10\^7 cells/m\^2

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells
Description: Three dose levels will be evaluated.~Group 1: CD19.CAR/28137ζ at 1×10\^6 cells/m\^2 and CD19.CAR/28ζ at 1×10\^6 cells/m\^2~Group 2: CD19.CAR/28137ζ at 5×10\^6 cells/m\^2 and CD19.CAR/28ζ at 5×10\^6 cells/m\^2~Group 3: CD19.CAR/28137ζ at 2×10\^7 cells/m\^2 and CD19.CAR/28ζ at 2×10\^7 cells/m\^2
Study: NCT01739218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 milligrams per kilogram \[mg/kg\] as IV infusion over 30-90 min every 3 weeks.
Study: NCT00631410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + mFOLFOX6
Description: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib + mFOLFOX6
Description: 50 mg/day, oral, administered on an outpatient basis for 2 weeks on, 2 weeks off (Schedule 2/2)
Study: NCT02818985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
Study: NCT01853631

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
Description: The primary goal of the expanded cohort is to further study the safety profiles of CAR-T cells in each of the disease settings, both with or without lymphodepleting chemotherapy given before CAR-T cell infusion.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
Description: The primary goal of the expanded cohort is to further study the safety profiles of CAR-T cells in each of the disease settings, both with or without lymphodepleting chemotherapy given before CAR-T cell infusion.
Study: NCT04035486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Drug: Osimertinib (Oral)~Other Names:~AZD9291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Drug: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study: NCT03857230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alfa (Primapur)
Description: During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa (Primapur)
Description: During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alfa (Gonal-F)
Description: During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.
Study: NCT03305861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ThuLEP
Description: Thulium laser enucleation of prostate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Green LEP
Description: Greenlight laser enucleation of prostate
Study: NCT04049383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg)
Description: The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level -1: 5 x 10\^5 CAR-20/19-T cells/kg
Study: NCT03857230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa (Gonal-F)
Description: During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.
Study: NCT02102880

Intervention type: GENETIC
Group type: OTHER
Intervention: the polymerase chain reaction (PCR)
Study: NCT02818426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCPVax
Study: NCT01920048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Therapy for Heart Failure
Description: The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Therapy for Heart Failure
Description: The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device Therapy for Heart Failure
Description: The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
Study: NCT01920048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Therapy for Heart Failure
Description: The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
Study: NCT01674348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P2202
Description: Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04049383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg)
Description: The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 0: 1 x10\^6 CAR-20/19-T cells/kg (starting dose level)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg)
Description: The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 0: 1 x10\^6 CAR-20/19-T cells/kg (starting dose level)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
Description: The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 1: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
Description: The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 1: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells
Description: The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~The dose expansion dose level is still to be determined and this section will be updated.
Study: NCT03366766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT01279122

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Nanoflex IOL
Description: Patients who were implanted with the Nanoflex IOL
Study: NCT00520611

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentives
Description: Participants call in their weight on daily basis. Participants must report under their daily targets to qualify for entry into lottery. Call-in weights are verified at monthly weigh-ins.
Study: NCT02217280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection with Gadolinium
Description: Gadavist (gadobutrol) injection is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system